TN Clinical Research Center
Welcome,         Profile    Billing    Logout  
 8 Trials 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gold, Michael
VOLIDO, NCT05386030: Saypha® VOLUME Lidocaine for Midface Augmentation

Completed
3
562
US
saypha® VOLUME Lidocaine, Juvéderm® Voluma™ XC
Croma-Pharma GmbH
Moderate to Severe Midface Volume Deficit
10/23
12/24
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
ENGOT en-21, NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
2/3
268
Europe, Canada, US, RoW
Navtemadlin, KRT-232, Navtemadlin Placebo
Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Endometrial Cancer
08/25
07/27
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
NCT04844983: A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Completed
2
44
US
STP705, STP705 Powder for Injection, Placebo Saline
Sirnaomics
Squamous Cell Carcinoma in Situ
08/22
12/22
GOG-3039, NCT04393285: Abemaciclib and Letrozole to Treat Endometrial Cancer

Active, not recruiting
2
53
US
Abemaciclib, Letrozole
Gynecologic Oncology Group, Eli Lilly and Company
Endometrial Cancer
12/24
12/25
HILO, NCT06297083: Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy

Withdrawn
2
130
NA
Peanut Oral Powder [PEANUT POWDER], Peanut oral immunotherapy, Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)
Murdoch Childrens Research Institute
Peanut Allergy
05/27
05/27
NCT05359133: A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

Recruiting
2
222
US
Tetrodotoxin, Halneuron, Placebo, Sterile 0.9% sodium chloride injection
Wex Pharmaceuticals Inc.
Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
12/25
07/26
GOG-3069, NCT05154487: A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Recruiting
2
51
US
Alpelisib Pill, Piqray, Fulvestrant injection, Faslodex
GOG Foundation, Novartis
Endometroid Endometrial Cancer
04/25
04/26
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
NCT04534660: Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler

Completed
N/A
21
US
SMI-01
Sofregen Medical, Inc., Symbio, LLC
Nasolabial Fold, Cheek Augmentation
08/21
06/23
NCT05507528: Evaluation of the Safety and Efficacy of REBORN System for Lipolysis Treatment

Completed
N/A
107
US, RoW
reborn treatment
Lightfective Ltd
LIPOLYSIS
11/23
11/23
NCT05882721: Treatment for Improvement of Cellulite Appearance Using Form Applicator

Completed
N/A
60
US
Sofwave
Sofwave Medical LTD
Cellulite
11/23
11/23
SyncAV, NCT04100148: Post-Market Trial

Active, not recruiting
N/A
1686
Europe, Canada, Japan, US, RoW
SyncAV programmed ON, Fixed AV delay
Abbott Medical Devices
Congestive Heart Failure
06/25
12/25
NCT05766943: Reduction of Myopotential Interference With Smart Pass in S-ICD Patients

Recruiting
N/A
71
US
Smart Pass ON, Smart Pass OFF
Medical University of South Carolina, Boston Scientific Corporation
Subcutaneous ICD, Myopotential Interference
12/24
12/24
NCT04794335: Visceral Afferents

Withdrawn
N/A
224
US
University of Pittsburgh, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Inflammatory Bowel Diseases
04/25
04/25
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
ACTRN12610000332022: A comparison of opt-in versus opt-out parental consent for participation in childhood vaccine safety surveillance using data linkage.

Active, not recruiting
N/A
1088
 
Discipline of Paediatrics, UNIVERSITY OF ADELAIDE, Australian Research Council Linkage Project grant
Vaccine safety surveillance using data linkage of administrative datasets
 
 
ACTRN12614001046695: Can e-Health improve post-marketing surveillance of drugs and vaccines? The Stimulated Telephone Assisted Rapid Safety Surveillance (STARSS) randomised controlled trial.

Recruiting
N/A
6550
 
University of Adelaide, WA Health, Murdoch Children's Research Institute, Glaxo-Smith Kline Australia Pty Ltd, Sanofi Aventis Australia Pty Ltd trading as Sanofi Pasteur , National Health and Medical Research Council
Post-marketing surveillance reporting of adverse events of vaccines , E-health
 
 

Download Options